drugset / Trial / NCT00461903

Efficacy of Perindopril to Prevent Recurrence of Atrial Fibrillation in Patients With Essential Hypertension

NCT00461903

Phase 3 Completed 316 enrolled Montreal Heart Institute Servier · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this 7- to 13-month study is to determine the efficacy of 8 mg/day oral perindopril to prevent the recurrence of atrial fibrillation (AF) in patients with essential hypertension.

Timeline

Start
2007-12
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Perindopril Small molecule 8 mg Oral